CCM
KRYS icon

CAAS Capital Management’s Krystal Biotech KRYS Stock Holding History

CAAS Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,121
Closed -$498K – 808
2021
Q4 		$498K Buy
+7,121
New +$414K 0.01% 540

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CAAS Capital Management's KRYS Position: Q1 2022 in Review

CAAS Capital Management sold out of Krystal Biotech (KRYS) in Q1 2022, closing a stake of 7,121 shares — an estimated $498K sold.

CAAS Capital Management first reported a position in KRYS in Q4 2021 and held it in 1 quarter. The position peaked at $498K in Q4 2021. 135 funds tracked by Wall St. Rank hold KRYS as of Q1 2022.

  • CAAS Capital Management reported no remaining Krystal Biotech position as of Q1 2022 after selling out during the quarter.
  • CAAS Capital Management sold 7,121 Krystal Biotech shares in Q1 2022, an estimated $498K.
  • CAAS Capital Management first reported a position in Krystal Biotech in Q4 2021 and held it in 1 quarter.
  • CAAS Capital Management's Krystal Biotech position peaked at $498K in Q4 2021.
  • 135 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2022.

Based on CAAS Capital Management's 13F filing for Q1 2022, filed 13 May 2022.